Traws Pharma (NASDAQ:TRAW) Announces Quarterly Earnings Results

Traws Pharma (NASDAQ:TRAW) released its quarterly earnings results on Monday. The company reported $95.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($7.00) by $102.66, Zacks reports.

Traws Pharma Price Performance

Shares of NASDAQ TRAW opened at $2.30 on Tuesday. Traws Pharma has a 12-month low of $2.02 and a 12-month high of $24.75. The company has a market capitalization of $8.40 million, a price-to-earnings ratio of -0.02 and a beta of 1.42. The firm’s 50 day simple moving average is $4.66.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.